期刊文献+

华法林药物遗传学基因CYP2C9和VKORC1单核苷酸多态性在广东汉族人群的分布研究 被引量:5

The study of single nucleotide polymorphisms distribution of CYP2C9 and VKORC1 associated with pharmacogenetics of warfarin in Guangdong Han Chinese
下载PDF
导出
摘要 目的探讨细胞色素P450(cytochrome P450,CYP450)家族中CYP2C9的单核苷酸多态性(single nucleotide polymorphisms,SNP)位点rs1057910和rs1799853以及维生素K环氧化物还原酶复合物亚基1(vitamin Kepoxide reductase complex subunit1,VKORC1)的rs9923231SNP位点在广东汉族的分布,为华法林(warfarin)个体化用药(personalizedmedicine)提供循证医学依据。方法利用Sequenom Mass Array iPLEX GOLD系统对215例广东地区人群的rs1057910,rs1799853和rs9923231三个位点进行基因分型,并分析各基因型分布频率。结果 rs1799853和rs9923231在广东汉族中无多态性分布,分别只有CC基因型和CT基因型。rs1057910在广东汉族中有两种基因型AA和AC,分布频率分别为0.921和0.079;等位基因A的频率为0.9605,C的频率为0.0395。结论在本研究中由于rs1799853和rs9923231在广东汉族中无多态性分布,基于本研究数据建议广东汉族华法林药物的检测位点应以rs1057910为主。 Objective To determined the frequencies of rs1799853, rs1057910 in CYP2C9 and rs9923231 in VKORC1, two warfarin related genes, in Guangdong Han Chinese population. Methods By Sequenom MassArray iPLEX GOLD System, rs1799853, rs1057910 and rs9923231 were genotyped in 215 individuals of Guangdong Han Chinese. The data were analyzed with SPSS13.0 to obtain the genotype frequencies and the allele frequencies. Results No polymorphism of rs1799853 and rs9923231 were found in the present population. Only genotype CC in rs1799853 and CT in rs9923231 was detected. There were two genotypes in rs1057910, AA and AC. The frequency of AA was 0.921 and AC was 0.079. The frequency of allele A was 0.9605 and C was 0.0395. Conclusion Our study recommends that the warfarin SNP test could mainly depend on rs1057910 in Guangdong Han Chinese owing to that there were no polymorphism distribution of in rs1799853 and rs9923231 in this population.
出处 《分子诊断与治疗杂志》 2012年第6期371-374,共4页 Journal of Molecular Diagnostics and Therapy
基金 广州市科技攻关计划(2008A1-E4151)
关键词 CYP2C9 VKORC1 单核苷酸多态性 华法林 CYP2C9 VKORC1 Single nucleotide polymorphism Warfarin
  • 相关文献

参考文献14

  • 1International Warfarin Pharmacogenetics Consortium, Klein T E, Altman R B, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data[J]. N Engl J Med, 2009, 360(8): 753-764.
  • 2Finkelman B S, Gage B F, Johnson J A, et warfarin dosing: tables versus algorithms[J] Cardiol, 2011, 57(5): 612-618 al. Genetic J Am Coil.
  • 3Lam M P, Cheung B M. The pharmacogenetics of the response to warfarin in Chinese[J]. Br J Clin Pharmacol,2012, 73(3): 340-347.
  • 4Takeuchi F, McGinnis R, Bourgeois S, et al. A genome-wide association study confirms VKORC 1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose[J]. PLoS Genet, 2009, 5(3): e1000433.
  • 5Lefferts J A, Schwab M C, Dandamudi U B, et al. Warfarin genotyping using three different platforms[J]. Am J Transl Res, 2010, 2(4): 441-446.
  • 6Wadelius M, Chen L Y, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism[J]. Hum Genet, 2007, 121(1): 23-34.
  • 7Limdi N A, Beasley T M, Crowley M R, polymorphisms, haplotypes and haplot warfarin dose among African-Americans Americans[J]. Pharmacogenomics, 2008, 9(1 et al. VKORCI ype and 0): 1 groups on European- 445-1458.
  • 8Jain K K. Textbook of Personalized Medicine[M]. Humana/ Springer, Totowa, NJ, USA, 2009.
  • 9Limdi N A, Veenstra D L. Warfarin pharmacogenetics[J]. Pharmacotherapy, 2008, 28(9): 1084-1097.
  • 10Liu Y, Zhong S L, Yang M, et al. Distribution of variant alleles association with warfarin pharmacokinetics and pharmacodynamics in the Han population in China[J] Beijing Da Xue Xue Bao, 2011, 43(6): 798-803.

同被引文献46

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部